Real-world Evaluation of Efficacy and Safety With Avelumab (BAVENCIO®) + Axitinib (INLYTA®) in Patients With aRCC in Multiple EU Countries
Studien-Status: geöffnet
Weitere Informationen finden Sie hier.
Clinical Research Platform On Renal Cell Carcinoma Treatment And Outcome (Registry Platform Renal Cell Carcinoma; CARAT)
Studien-Status: geöffnet
Weitere Informationen finden Sie hier.
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy
Studien-Status: geöffnet
Weitere Informatioen finden Sie hier.
A National, Prospective, Non-Interventional Study (NIS) in Patients With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab And Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy
Studien-Status: geöffnet
Weitere Informationen finden Sie hier.
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Actual Study Start Date : March 20, 2019
Studien-Status: geöffnet
Weitere Informationen finden Sie hier.
Ansgar Nehus (Ltd. study nurse)
Michael Grenzebach (study nurse)
Anika Kunz (study nurse)
Nadine Rosenow (study nurse)
Terminvereinbarung
Montag bis Donnerstag: 10 - 14 Uhr
E uroonkologie(at)ukmuenster(dot)de
T +49 (0)251- 83 48 12 6
IN NOTFÄLLEN
T +49 (0)251- 83 47 44 6 oder
T +49 (0)251- 83 48 00 1
Univ.-Prof. Dr.med. Martin Bögemann, FEBU
Leiter der Studienzentrale
E-Mail: martin.boegemann(at)ukmuenster(dot)de
Dr. med. Katrin Schlack, FEBU
OA für den Bereich Uroonkologie
Prüfärztin
E-Mail: Katrin.Schlack(at)ukmuenster(dot)de
